DUBAI, United Arab Emirates, February 10, 2011 /PRNewswire/ -- The Health
Care Division of ALQAEM International FZE, the exclusive master distributor
for the M.E.N.A. region of the UFIT(R) noninvasive medical device created by
Biosign Technologies Inc. of Canada, is pleased to announce that it has
placed orders for delivery this quarter and will begin a limited release in
March to those M.E.N.A. regions that recognize the CE Mark for medical device
registration.
ALQAEM and Biosign jointly announced the very successful public debut of the UFIT(R) Heath Monitoring System at Arab Health 2011 in Dubai, UAE (Jan 24th - 27th), where for the first time, the features and benefits of the UFIT(R)TEN-20 non-invasive blood pressure and blood glucose monitor were demonstrated to the public locally in the Gulf Region.
UFIT(R) TEN-20 is an online medical device for self-monitoring of blood pressure and blood glucose. The device takes the pulse at the wrist through an inflatable cuff and immediately produces pulse trace, blood pressure and blood glucose measurement results. UFIT(R) TEN-20 does not require any type of blood sampling or under-skin implant. All measurements are indirect, noninvasive, and passive and do not produce any hazardous waste. The results are stored on Biosign servers along with the digital test sample. UFIT(R) TEN-20 is approved under ISO 13485 for the non-invasive measurement of blood pressure and blood glucose, and carries the CE Mark.
John Rizvi, Managing Director of ALQAEM stated: "At Arab Health 2011 we received a lot of attention from key government leaders and retail partners from UAE, Saudi Arabia, Egypt and several other M.E.N.A. countries. We will now launch this remarkable system to clinical and institutional clients, which will tend to maximize the productivity of each UFIT(R)PAD unit, and generate additional goodwill and media attention for both ALQAEM and Biosign."
SOURCE ALQAEM International FZE (Healthcare Division)
Advertisement
ALQAEM and Biosign jointly announced the very successful public debut of the UFIT(R) Heath Monitoring System at Arab Health 2011 in Dubai, UAE (Jan 24th - 27th), where for the first time, the features and benefits of the UFIT(R)TEN-20 non-invasive blood pressure and blood glucose monitor were demonstrated to the public locally in the Gulf Region.
Advertisement
UFIT(R) TEN-20 is an online medical device for self-monitoring of blood pressure and blood glucose. The device takes the pulse at the wrist through an inflatable cuff and immediately produces pulse trace, blood pressure and blood glucose measurement results. UFIT(R) TEN-20 does not require any type of blood sampling or under-skin implant. All measurements are indirect, noninvasive, and passive and do not produce any hazardous waste. The results are stored on Biosign servers along with the digital test sample. UFIT(R) TEN-20 is approved under ISO 13485 for the non-invasive measurement of blood pressure and blood glucose, and carries the CE Mark.
John Rizvi, Managing Director of ALQAEM stated: "At Arab Health 2011 we received a lot of attention from key government leaders and retail partners from UAE, Saudi Arabia, Egypt and several other M.E.N.A. countries. We will now launch this remarkable system to clinical and institutional clients, which will tend to maximize the productivity of each UFIT(R)PAD unit, and generate additional goodwill and media attention for both ALQAEM and Biosign."
Contact Information:
ALQAEM International FZE
(Healthcare Division)
Mr. John Rizvi, Managing Director
Phone: +971-6-557-8661
Email: [email protected]
Website: http://www.alqaemhealthcare.com
Contact: Contact Information: ALQAEM International FZE, (Healthcare
Division), Mr. John Rizvi, Managing Director, Phone: +971-6-557-8661, Email:
[email protected]SOURCE ALQAEM International FZE (Healthcare Division)
